Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890039 | 0.87 | LMNA (0.77) | LMNAHSD17B10PTGS2PKMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7981337 | 0.85 | LMNA (0.74) | LMNAHSD17B10PTGS2PKMSMN1; SMN2 | |
| Bromide SCHEMBL351809 | 0.85 | LMNA (0.74) | LMNAHSD17B10PTGS2PKMSMN1; SMN2 | |
| Bromide SCHEMBL28098177 | 0.85 | LMNA (0.74) | LMNAHSD17B10PTGS2PKMSMN1; SMN2 | |
| SCHEMBL18031133 | 0.85 | PTGS2 (0.64) | LMNAHSD17B10PTGS2ALDH1A1L3MBTL1 | |
| SCHEMBL18031138 | 0.83 | PTGS2 (0.63) | LMNAHSD17B10PTGS2ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5459649 | 0.83 | L3MBTL1 (0.73) | LMNAHSD17B10PTGS2PKMSMN1; SMN2 | |
| SCHEMBL15452507 | 0.81 | ALDH1A1 (0.71) | LMNAHSD17B10PTGS2PKMSMN1; SMN2 | |
| SCHEMBL18031140 | 0.80 | PTGS2 (0.53) | LMNAHSD17B10PTGS2L3MBTL1KMT2A | |
| SCHEMBL18031614 | 0.80 | CA12 (0.54) | LMNAHSD17B10PTGS2PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244462-A1 | 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-08-25 | — | — | US | disclosed |
| US-20160244462-A1 | 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-08-25 | — | — | US | disclosed |
| CN-1061041-C | Piperidine derivatives | GLAXO GROUP LTD (GB) | 2001-01-24 | — | — | CN | disclosed |
| US-5843966-A | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| US-5703240-A | ANALGESICS; ANTIINFLAMMATORY AGENTS; NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS; GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-30 | — | — | US | disclosed |
| CN-1135218-A | Piperidine derivatives | GLAXO GROUP LTD (GB) | 1996-11-06 | — | — | CN | disclosed |
| EP-0720609-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008549-A1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LIMITED (GB) | 1995-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244462-A1 | 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF | XDH, DHFR, G6PD | LMNA 3932/4885HSD17B10 1567/4885PTGS2 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.